Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06401551 · ClinicalTrials.gov registry record · NA

Clareon PanOptix Pro vs. Clareon PanOptix - Study B

A NA study of Presbyopia and Aphakia, sponsored by Alcon Research.

Completed
Registry status
NA
Development phase
71
Enrollment target
8
Study locations

NCT06401551 is a NA study of Presbyopia and Aphakia that has completed, run by Alcon Research. The registered enrollment target is 71 participants, below the 269-participant average among 38 other Presbyopia trials with a reported enrollment target (74% lower). The trial reports 8 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06401551, a NA study of Presbyopia and Aphakia, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
NA
Development phase
71 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.

Conditions Studied

Interventions

  • DEVICE CPO Pro IOL
  • DEVICE CPO IOL
  • PROCEDURE Cataract Surgery

Study Locations (8)

California

  • Wolstan & Goldberg Eye Associates - Torrance

Michigan

  • Grosinger, Spigelman & Grey Eye Surgeons, P.C. - Bloomfield Hills

Missouri

  • Moyes Eye Center - Kansas City

Ohio

  • Cincinnati Eye Institute - Cincinnati

South Carolina

  • Carolina Eye Care Physicians - Charleston

Tennessee

  • Vision for Life - Nashville

Texas

  • Houston Eye Associates - Houston

Utah

  • The Eye Institute of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2024-06-18
Est. Completion 2025-04-30
Phase NA

Sponsor

Alcon Research

275 total trials

What the Registry Record Tells You About NCT06401551

The ClinicalTrials.gov registry entry for NCT06401551 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 269-participant average among 38 other Presbyopia trials with a reported enrollment target (74% lower). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Presbyopia appearing as the primary indexed condition, and to 3 interventions - of which CPO Pro IOL is the first listed.

NCT06401551 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Michigan, Missouri.

Frequently Asked Questions

What is clinical trial NCT06401551 about?

NCT06401551 is a clinical study titled "Clareon PanOptix Pro vs. Clareon PanOptix - Study B". The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™ PanOptix™ Trifocal IOL.

What is the current status of trial NCT06401551?

This trial is currently completed. It is a NA study. The enrollment target is 71 participants. The study started on 2024-06-18. Estimated completion is 2025-04-30.

What conditions does trial NCT06401551 study?

This clinical trial studies the following conditions: Presbyopia, Aphakia.

What interventions are being tested in trial NCT06401551?

The interventions under investigation include: CPO Pro IOL (DEVICE), CPO IOL (DEVICE), Cataract Surgery (PROCEDURE).

Who is sponsoring clinical trial NCT06401551?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06401551 being conducted?

This trial has 8 study locations across California, Michigan, Missouri, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Presbyopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.